Institute of Biomedical Research Corp.
MRES · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $49 | $45 | $29 | $0 |
| % Growth | 9.8% | 53.1% | – | – |
| Cost of Goods Sold | $28 | $37 | $21 | $0 |
| Gross Profit | $21 | $9 | $9 | $0 |
| % Margin | 43.2% | 19% | 29.5% | – |
| R&D Expenses | -$110 | $209 | $4 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $888 | $1,596 | $728 | $167 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $778 | $1,805 | $733 | $167 |
| Operating Income | -$757 | -$1,796 | -$724 | -$167 |
| % Margin | -1,528.7% | -3,985% | -2,458.5% | – |
| Other Income/Exp. Net | $17 | $3,153 | $290 | $0 |
| Pre-Tax Income | -$740 | $1,357 | -$433 | -$167 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$633 | $1,330 | -$433 | -$167 |
| % Margin | -1,278.6% | 2,950.3% | -1,472% | – |
| EPS | -0 | 0.001 | -0 | -0 |
| % Growth | -133.3% | 300% | -50% | – |
| EPS Diluted | -0 | 0.001 | -0 | -0 |
| Weighted Avg Shares Out | 2,663,612 | 2,371,424 | 1,454,642 | 915,789 |
| Weighted Avg Shares Out Dil | 2,663,612 | 2,371,424 | 1,454,642 | 915,789 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $1 | $0 |
| Interest Expense | $15 | $37 | $49 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$724 | $1,393 | -$384 | -$167 |
| % Margin | -1,463.5% | 3,091.4% | -1,304.5% | – |